MPC 3100

Drug Profile

MPC 3100

Alternative Names: MPC-3100

Latest Information Update: 26 Nov 2012

Price : $50

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Antineoplastics; Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 11 May 2012 Myrexis intends to out-license all its preclinical and clinical programmes, including MPC 3100, for further development
  • 28 Mar 2012 Adverse events and pharmacodynamics data from a phase I trial in Cancer presented at the 243rd National Meeting of the American Chemical Society (243rd-ACS-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top